Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02606305
Title Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

endometrial cancer

Therapies

Bevacizumab

Carboplatin

Doxorubicin

Mirvetuximab Soravtansine

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Alabama Birmingham Alabama United States Details
University of California at Los Angeles Los Angeles California United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
City of Hope Reno Nevada United States Details
The Ohio State University Hilliard Ohio 43026 United States Details
Peggy and Charles Stephenson Oklahoma Cancer Center Oklahoma City Oklahoma 73104 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut Leuven 3000 Belgium Details
Juravinski Cancer Center Calgary Canada Details
Tom Baker Cancer Center Hamilton Canada Details
Centre Hospitalier de l'universite de Montreal (CHUM) Montreal Canada Details
McGill University Health Center Montreal Canada Details
Princess Margaret Cancer Center Toronto Canada Details
Hospital Vall D'Hebron Barcelona Spain Details
MD Anderson Madrid 28033 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field